Edwards Lifesciences Co. (NYSE:EW - Get Free Report) VP Donald E. Bobo, Jr. sold 6,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at $3,555,402. This represents a 12.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Edwards Lifesciences Trading Up 0.3 %
Shares of NYSE EW traded up $0.23 during midday trading on Monday, reaching $76.23. The stock had a trading volume of 3,899,190 shares, compared to its average volume of 4,438,355. The company's 50 day moving average price is $72.67 and its 200 day moving average price is $69.58. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The firm has a market cap of $44.96 billion, a price-to-earnings ratio of 11.00, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10.
Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. As a group, sell-side analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current year.
Analyst Ratings Changes
EW has been the subject of several recent analyst reports. Robert W. Baird dropped their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. Barclays increased their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday. Wolfe Research downgraded shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Canaccord Genuity Group increased their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research note on Thursday. Finally, Morgan Stanley boosted their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $79.95.
Get Our Latest Research Report on EW
Institutional Investors Weigh In On Edwards Lifesciences
Several institutional investors and hedge funds have recently made changes to their positions in EW. Crowley Wealth Management Inc. acquired a new stake in Edwards Lifesciences in the fourth quarter worth $26,000. Millstone Evans Group LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth about $29,000. FSA Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at about $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences in the 4th quarter valued at about $30,000. Finally, Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences during the 3rd quarter worth approximately $32,000. Institutional investors own 79.46% of the company's stock.
About Edwards Lifesciences
(
Get Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Featured Articles
Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
